MK
ALNY icon

MASTERINVEST Kapitalanlage’s Alnylam Pharmaceuticals ALNY Stock Holding History

MASTERINVEST Kapitalanlage’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Buy
1,251
+72
+6% +$21.7K 0.03% 234
2026
Q1 		$390K Buy
+1,179
New +$401K 0.04% 232
2025
Q4 		– Sell
-494
Closed -$225K – 268
2025
Q3 		$225K Buy
+494
New +$201K 0.02% 260

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MASTERINVEST Kapitalanlage's ALNY Position: Q2 2026 in Review

MASTERINVEST Kapitalanlage increased its Alnylam Pharmaceuticals (ALNY) stake by 6.1% in Q2 2026, buying an estimated $21.7K and bringing the position to 1,251 shares worth $377K. The position accounts for 0.03% of the portfolio, ranked #234.

MASTERINVEST Kapitalanlage first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $390K in Q1 2026. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • MASTERINVEST Kapitalanlage held 1,251 shares of Alnylam Pharmaceuticals worth $377K as of Q2 2026.
  • MASTERINVEST Kapitalanlage bought 72 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $21.7K.
  • Alnylam Pharmaceuticals made up 0.03% of MASTERINVEST Kapitalanlage's portfolio in Q2 2026, its #234 holding.
  • MASTERINVEST Kapitalanlage first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • MASTERINVEST Kapitalanlage's Alnylam Pharmaceuticals position peaked at $390K in Q1 2026.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on MASTERINVEST Kapitalanlage's 13F filing for Q2 2026, filed 17 Aug 2026.